NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.71
-0.01 (-0.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.72
Open1.72
Bid1.72 x 800
Ask1.75 x 35000
Day's Range1.71 - 1.75
52 Week Range0.73 - 2.75
Volume3,829,238
Avg. Volume9,597,880
Market Cap651.753M
Beta2.96
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • 3 Biotech Stocks That Will Thrive Amid Market Instability
    InvestorPlace2 days ago

    3 Biotech Stocks That Will Thrive Amid Market Instability

    The U.S. stock market is facing a severe volatility since the last couple of months despite a strong start this year. This downside can mainly be attributable to a potentially damaging trade war between the world’s two largest economies, United States and China, since this February.Source: Shutterstock

  • Buy Novavax After Its Latest Pullback?
    Motley Fool4 days ago

    Buy Novavax After Its Latest Pullback?

    Novavax has a couple of promising experimental vaccines. But could even more dilution be around the corner?

  • GlobeNewswire5 days ago

    Novavax Announces Closing of Public Offering

    GAITHERSBURG, Md., April 16, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced ...

  • GlobeNewswire5 days ago

    Novavax Announces Closing of Public Offering

    GAITHERSBURG, Md., April 16, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced the closing of the underwritten ...

  • ACCESSWIRE8 days ago

    Today’s Research Reports on Stocks to Watch: Novavax and Pfizer

    NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on ...

  • Here's Why Novavax, Inc. Is Sinking
    Motley Fool9 days ago

    Here's Why Novavax, Inc. Is Sinking

    Shares plunged after the clinical-stage vaccine maker gave details on the pricing of its recently announced common stock offering.

  • MarketWatch9 days ago

    Novavax's stock plunges on heavy volume after public offering prices at deep discount

    Shares of Novavax Inc. tumbled 16% in active premarket trade Thursday, after the biotechnology company said its relatively large public offering of stock priced at a deep discount. Volume topped 8.5 million ...

  • GlobeNewswire10 days ago

    Novavax Prices Public Offering of Common Stock

    GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced ...

  • GlobeNewswire10 days ago

    Novavax Prices Public Offering of Common Stock

    GAITHERSBURG, Md., April 11, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it has priced an underwritten ...

  • Novavax announces plans for public offering
    American City Business Journals10 days ago

    Novavax announces plans for public offering

    Details of the offering — including how many shares the company would sell, at what price, and when — are still being hammered out.

  • GlobeNewswire10 days ago

    Novavax Announces Proposed Public Offering of Common Stock

    GAITHERSBURG, Md., April 11, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it intends to offer ...

  • Pick 3 Biotech Money-Spinning Bets Amid Market Instability
    Zacks15 days ago

    Pick 3 Biotech Money-Spinning Bets Amid Market Instability

    The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

  • Investopedia16 days ago

    Top 3 Healthcare Penny Stocks for 2018

    These three healthcare penny stocks are poised for positive performance in 2018.

  • 3 Top Small-Cap Biotech Stocks for Aggressive Investors
    Motley Fool18 days ago

    3 Top Small-Cap Biotech Stocks for Aggressive Investors

    These small biotechs could be huge winners. But they also have huge risks.

  • GlobeNewswire19 days ago

    Novavax to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Vaccine Congress

    Update on RSV F Vaccine Phase 3 Prepare (TM) trial for infants via maternal immunization Results from Phase 1/2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose ...

  • GlobeNewswire19 days ago

    Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress

    Update on RSV F Vaccine Phase 3 Prepare™ trial for infants via maternal immunization Results from Phase 1/ 2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose ...

  • Analysts’ Ratings for Sorrento and Its Peers in March 2018
    Market Realist23 days ago

    Analysts’ Ratings for Sorrento and Its Peers in March 2018

    Sorrento Therapeutics (SRNE) is a clinical-stage biotechnology company. Its research programs are targeted at autoimmune, inflammatory, and neurodegenerative diseases and pain indications. Essentially, Sorrento Therapeutics is an antibody-centric company and leverages its G-MAB library to generate product candidates.

  • What Analysts Recommend for AbbVie and Peers in March 2018
    Market Realist23 days ago

    What Analysts Recommend for AbbVie and Peers in March 2018

    AbbVie (ABBV) is a global biopharmaceutical company with a focus on research. AbbVie’s pipeline also includes medicines for cystic fibrosis and women’s health. Of the 23 analysts covering AbbVie in March 2018, four analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating.

  • What’s behind Omeros’s Cash Flow
    Market Realist23 days ago

    What’s behind Omeros’s Cash Flow

    An Investor's Overview of Omeros

  • Analysts’ Ratings for Omeros and Peers in March 2018
    Market Realist23 days ago

    Analysts’ Ratings for Omeros and Peers in March 2018

    An Investor's Overview of OmerosCompany overview

  • Forget Merck: Novavax, Inc. Is a Better Vaccine Stock
    Motley Fool24 days ago

    Forget Merck: Novavax, Inc. Is a Better Vaccine Stock

    Novavax better than Merck? For some investors, the answer could be "yes."

  • Exploring Xencor’s Cash Flows
    Market Realist26 days ago

    Exploring Xencor’s Cash Flows

    In 2017, Xencor generated $31.9 million from investing activities compared to its expenditure of $213.6 million in 2016. The company’s investing activities mainly consist of the purchase and sale of marketable securities and the acquisition of intellectual property and equipment. In 2017, Xencor used $39.2 million in marketable securities.

  • Analysts’ Recommendations for Xencor and Its Peers in March
    Market Realist26 days ago

    Analysts’ Recommendations for Xencor and Its Peers in March

    Xencor’s proprietary technology platform, XmAb, enables it to create antibody product candidates for the treatment of autoimmune and allergic diseases. Of the six analysts covering Xencor in March 2018, three have given the stock “strong buy” ratings, and two have given it “buy” ratings, while one analyst has given it a “hold” rating. The mean rating for the stock is 1.67, and its target price is $36.67.

  • When Will Novavax Inc (NASDAQ:NVAX) Become Profitable?
    Simply Wall St.29 days ago

    When Will Novavax Inc (NASDAQ:NVAX) Become Profitable?

    Novavax Inc’s (NASDAQ:NVAX): Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The US$685.25MRead More...

  • Analyzing Novavax’s Cash Flows
    Market Realistlast month

    Analyzing Novavax’s Cash Flows

    How Is Novavax Positioned in 2018?